New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access
New Treatments for Hepatitis C Virus: Strategies for ...
www.aidsportal.org/web/guest/resource?id=6b3acf6a-14a0-4e33...
Mar 19, 2014 - New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access. By Pauline Londeix, technical advisor to Médecins du Monde, ...
[PDF]
Download the Full Report here - ITPC-MENA
www.itpcmena.org/.../new_treatment_for_hepc__strategies_for_achievin...
by P Londeix - 2014
Mar 4, 2014 - Strategies for Achieving. Universal Access .... pharmaceutical companies, universal access would be prac- tically unachievable, even in .... expanding access to new HCV treatments, and compares them in order to determine ...
===============================
Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C
Forbes - Jun 9, 2014
Wall Street has already declared a winner in the race to develop new treatments for hepatitis C, a virus
that infects 3.2 million Americans that is the leading cause of liver
transplantation in the United States. It's Gilead Sciences. Everyone
knows that Gilead's Sovaldi, already the best drug ... It's just
impossible.” Gilead hopes to launch a three-drug, one-pill hepatitis C treatment this fall, and is expected to mop up a huge number of hepatitis C patients. Already, Sovaldi's rapid uptake in usage has led to protests from ...
Merck & Co to buy Idenix to boost hepatitis C drugs portfolio
Reuters - Jun 9, 2014
The payoff for Merck could come from a triple therapy that may cure patients with all genotypes, or strains, of the hepatitis C virus in as little as four to six weeks, its research chief, Roger Perlmutter, said in an interview. "An ideal therapy ... In a recent mid-stage trial, Merck's two-drug combo cured 98 percent of previously untreated patients with genotype 1, the most common and hardest to treat variant of hepatitis C. The Idenix drug in .... Bankruptcy Law · California Legal · New York Legal · Securities Law. Support & ...
Merck & Co. to Buy Hepatitis-Drug Maker Idenix
Bloomberg - Jun 9, 2014
Buying the Cambridge, Massachusetts-based company will help Merck in
the competition to develop a daily, all-oral regimen that treats
different strains of the viral infection and doesn't include ribavirin, a standard therapy for hepatitis C that has serious side effects. In April, Merck said its once-a-day hepatitis C pill, which combined two drugs, stopped ... Merck shares gained less than 1 percent to $57.94 at the close in New York. Idenix shares more than tripled to $23.79. Idenix came to Merck after another company ...
Merck Bids $3.8 Billion for an Edge in Hepatitis
New York Times - Jun 9, 2014
New drugs are transforming the treatment of hepatitis C, replacing injections with pills, as well as increasing the cure rates, reducing side effects and cutting the duration of treatment to as little as eight to 12 weeks from as long as a year. But the new pills for ... to 18 weeks of treatment. Adding a drug from Idenix to those two drugs could allow for a once-a-day pill that could treat all subtypes of the virus in as little as four weeks, Dr. Roger Perlmutter, who heads research and development for Merck, said in an interview.
Merck to buy Idenix for $3.9 billion for Hepatitis C
NorthJersey.com - Jun 9, 2014
based company will help Merck in the race to develop a daily, all-oral regimen that treats different strains of the viral infection and doesn't include ribavirin, a standard treatment for hepatitis C that has serious side effects. In April, Merck ... "The big pharma companies understand that the prevalence of people with hep-C
is so big that the market is going to be around for the next 10 years,"
said Jason Kolbert, senior managing director with Maxim Group LLC in New York, in a telephone interview Monday. "It's a very fair ...
Merck agrees to buy Idenix for $3.85 billion
USA TODAY - Jun 9, 2014
Drug companies are racing to test new and potentially lucrative treatments for hepatitis
C. An estimated 3 million people in the USA are chronically infected
with hepatitis C, the nation's leading cause of liver cancer and liver
transplants. About half or more of ... It has three drugs in clinical
development to treat the hepatitis C virus, known as HCV. Merck's ... The addition of the Idenix portfolio to our breakthrough treatments already under development brings us one step closer to achieving this goal." The Centers for ...
Merck to buy hepatitis C treatment maker Idenix Pharma
The Globe and Mail - Jun 9, 2014
based Idenix – seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals. Hepatitis C has become one of the hottest categories in drug research as companies ...
Merck to Pay $3.85B for Hepatitis C Drug Developer
ABC News - Jun 9, 2014
Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy
without injections and debilitating side effects. Some have had their
promising candidates fail after extensive testing, due to dangerous side
effects, but Gilead Sciences Inc. ... Three Idenix experimental drugs
have reached human testing and one, samatasvir, is in mid-stage testing. It's in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs ...
UPDATED: Merck scoops up troubled Idenix's hep C drugs in $3.85B buyout
FierceBiotech - Jun 9, 2014
Eight months after it promised to go on a shopping spree for new
experimental drugs, Merck ($MRK) has come up with a $3.85 billion cash
deal to buy out Idenix, a biotech company best known for its setbacks in
hepatitis C drug research. The deal instantly broadens Merck's ... Hepatitis C was once one
of the hottest fields in biotech for M&A, but the deal-making
cooled dramatically over the past two years as Gilead surged forward and
other companies experienced setbacks. This morning, though, the focus
is back on ...
Merck to buy Cambridge's Idenix in $3.85b deal
Boston Globe - Jun 10, 2014
The pharmaceutical giant Merck & Co. agreed on Monday to pay $3.85
billion for a Cambridge biotech that is developing drugs to cure hepatitis C,
a staggering price for a small company with fewer than 100 employees.
Merck's agreement to buy 16-year-old Idenix Pharmaceuticals Inc. is the latest
sign the Boston-area biotechnology cluster has become a powerful magnet
for global drug makers in search of breakthrough medicines — and huge
profits. Continue reading .... 1/28/14: Abby fight may be with mediocrity.
Investors eye Achillion for next big pharma deal
CNBC.com - Jun 11, 2014
While AbbVie, Bristol-Myers and J&J are in the race with Merck and Gilead to develop new treatments for hepatitis C,
a market estimated to be worth more than $20 billion in 2018, those
three companies are left without nucs, Bayko noted. Nucs are considered
to be a key ... $1B profit on Idenix deal. The goal among drugmakers now
is to develop a single pill that patients can take once a day, with
fewer side effects, that will cure the virus for all patients in the shortest period of time—potentially in a matter of weeks.
No comments:
Post a Comment